The central nervous system (CNS) is shielded from threats by the blood-brain barrier (BBB), a selective physiological gatekeeper. It does, however, also provide a serious obstacle to the delivery of therapeutic medicines to the brain, making it difficult to treat neurological conditions such as glioblastoma, epilepsy, and Alzheimer's. With their focused distribution, regulated release, targeted delivery, and improved BBB penetration, nanocarrier-based methods act as a reassuring alternative. This chapter examines drug delivery obstacles, the anatomy of the blood-brain barrier, and the function of advanced nanocarriers, including exosomes, liposomes, dendrimers, and polymeric and lipid nanoparticles. Additionally, it addresses recent developments in receptor-mediated targeting, surface modifications, stimuli-responsive administration, and regulatory issues, as well as future objectives in brain-targeted nanomedicine.
Author
(s) Details
Venkatalakshmi
Ranganathan
Department of Pharmaceutics, Crescent School of Pharmacy, B.S.
Abdur Rahman Crescent Institute of Science & Technology, Chennai-600048,
India.
Roshni.
N
Department of Pharmaceutics, Crescent School of Pharmacy, B.S.
Abdur Rahman Crescent Institute of Science & Technology, Chennai-600048,
India.
Preethi.
M
Department of Pharmaceutics, Crescent School of Pharmacy, B.S.
Abdur Rahman Crescent Institute of Science & Technology, Chennai-600048,
India.
Sasikala
Chinnappan
Department of Pharmaceutical Biology, UCSI University, Taman
Connaught, 56000 Cheras, Malaysia.
Please see the book here:- https://doi.org/10.9734/bpi/psnid/v6/5443
No comments:
Post a Comment